Smoking associated with MDS mutations, progression
Results from a prospective study presented at the American Society of Hematology Annual Meeting & Exposition showed that tobacco smoking was associated with
Meetings / Conferences
MDS
Society Updates
Save the date for SOHO 2025 in Houston, Texas
The Society of Hematologic Oncology (SOHO) has announced that its 2025 meeting will be held between Wednesday, September 3, 2025, and Saturday, September
Cellular Therapy
T-Cell Lymphoma
CTX130 demonstrates potential in relapsed or refractory T-cell lymphoma
The chimeric antigen receptor (CAR)-T cell therapy CTX130 (volamcabtagene durzigedleucel) showed encouraging results in patients with heavily pretreated relapsed or refractory T-cell lymphoma,
Meetings / Conferences
66th American Society of Hematology Annual Meeting & Exposition
Novel immune checkpoint blocker ‘well-tolerated’ in DLBCL
FS118, a new potential immune checkpoint blocker, was well tolerated in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) with
Multiple Myeloma
MRD2STOP trial supports discontinuation of maintenance therapy in MM patients with low MRD negativity
Maintenance therapy discontinuation in patients with deep measurable residual disease (MRD) negativity (<10⁻⁶ or <10⁻⁷) is associated with low rates of disease resurgence
Society Updates
Why join the Society of Hematologic Oncology (SOHO)?
Rami Komrokji, MD, of the Moffitt Cancer Center in Tampa, Florida, and 2024-2025 SOHO President Phillip Scheinberg, MD, PhD, of the Hospital Sao
Meetings / Conferences
66th American Society of Hematology Annual Meeting & Exposition
Lymphoma
CtDNA levels could serve as an early predictor of treatment success in LBCL
CtDNA is a valuable biomarker for monitoring disease burden and predicting durable clinical benefit in second-line large B-cell lymphoma (LBCL) treatment, according to
Meetings / Conferences
66th American Society of Hematology Annual Meeting & Exposition
Lymphoma
Researchers call for standardized reporting of toxicity outcomes in phase 1 lymphoma trials
Clearer standardized reporting of toxicity outcomes in phase 1 lymphoma trials is required for improved transparency and communication in drug development, according to
Meetings / Conferences
Leukemia
Study explores FLT3-targeted therapy for patients with AML
The ECOG-ACRIN MM20A-EA02 trial, part of the myeloMATCH precision medicine initiative from the US National Institutes of Health, is evaluating a novel combination
Meetings / Conferences
MDS
Key factors drive MDS progression
Patients with myelodysplastic syndromes (MDS) face varying progression risks based on clinical factors such as low hemoglobin levels and platelet counts, according to